(Bloomberg) -- Drug price increases hurt patients and disruptthe supply of medicine in the U.S., experts told a Senate panelthat’s investigating the industry.

While companies should be rewarded for developing new drugs, thesystem “never anticipated companies acquiring off- patent drugs andthen jacking up their prices to enormous heights,” SenatorSusan Collins, a Maine Republican, said in a prepared statement atthe start of the Senate Special Committee on Aging’s hearingWednesday.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.